Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

112.62 -0.65 (-0.57%)

Delayed Quote Updated: 12:49 PM EDT, Oct 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

29 30 Next >

Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress

May 14, 2024

From Incyte

Via Business Wire

Tech Stocks Inch Higher Ahead Of Key Inflation Data, GameStop Skyrockets, Tencent Fuels China Rally: What's Driving Markets Monday? ↗

May 13, 2024

Wall Street kicked off a data-heavy week on a mixed note as traders await key inflation updates and remarks from Fed Chair Jerome Powell in the coming days.

Via Benzinga

Topics Economy

GameStop, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday ↗

May 13, 2024

Via Benzinga

Peeling Back The Layers: Exploring Incyte Through Analyst Insights ↗

April 23, 2024

Via Benzinga

Incyte Announces Intention to Buy Back up to $2.0 Billion of its Common Stock

May 13, 2024

From Incyte Corporation

Via Business Wire

The 3 Best Biotech Stocks to Buy in May 2024 ↗

May 09, 2024

If you have the appetite for the risk inherent in the biotech sector, here are three biotech stocks to buy in May.

Via InvestorPlace

NASDAQ:INCY appears to be flying under the radar despite its strong fundamentals. ↗

May 08, 2024

INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals.

Via Chartmill

Incyte to Present at Upcoming Investor Conference

May 02, 2024

From Incyte

Via Business Wire

INCY Stock Earnings: Incyte Misses EPS, Misses Revenue for Q1 2024 ↗

April 30, 2024

INCY stock results show that Incyte missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

NASDAQ:INCY stands out as a growth opportunity that won't break the bank. ↗

April 05, 2024

NASDAQ:INCY is showing good growth, while it is not too expensive.

Via Chartmill

NASDAQ:INCY, a growth stock which is not overvalued. ↗

March 15, 2024

Despite its growth, NASDAQ:INCY remains within the realm of affordability.

Via Chartmill

Incyte Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) ↗

March 12, 2024

Via Benzinga

Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs

April 30, 2024

From Incyte

Via Business Wire

Don't overlook NASDAQ:INCY—a stock with solid growth prospects and a reasonable valuation. ↗

April 26, 2024

In the world of growth stocks, NASDAQ:INCY shines as a value proposition.

Via Chartmill

Incyte Should Consider Significant Stock Buyback And Prioritize R&D, Analyst Recommends ↗

April 23, 2024

Incyte acquires Escient Pharmaceuticals for $750 million, bolstering its pipeline. Cantor Fitzgerald initiates coverage with a Neutral rating, citing undervaluation concerns despite strong cash flow.

Via Benzinga

Incyte Announces Acquisition of Escient Pharmaceuticals and its Pipeline of First-in-Class Oral MRGPR Antagonists

April 23, 2024

From Incyte and Escient Pharmaceuticals

Via Business Wire

NASDAQ:INCY stands out as a stock that provides good value for the fundamentals it showcases. ↗

March 04, 2024

INCYTE CORP (NASDAQ:INCY): good value for what you're paying.

Via Chartmill

When you look at NASDAQ:INCY, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

April 17, 2024

Don't overlook INCYTE CORP (NASDAQ:INCY)—it's a hidden gem with strong fundamentals and an attractive price tag.

Via Chartmill

Incyte to Report First Quarter Financial Results

April 11, 2024

From Incyte

Via Business Wire

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗

April 06, 2024

ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...

Via Talk Markets

Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

April 01, 2024

From Incyte

Via Business Wire

Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 29, 2024

From Incyte

Via Business Wire

For those who appreciate value investing, NASDAQ:INCY is a compelling option with its solid fundamentals. ↗

March 26, 2024

INCYTE CORP (NASDAQ:INCY) is an undervalued gem with solid fundamentals.

Via Chartmill

Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead ↗

March 11, 2024

Don't fall for the siren song of penny stocks. Rather, fill your portfolio with companies that have a proven track record of success.

Via InvestorPlace

Incyte Announces New Data from Phase 2 Study Evaluating Ruxolitinib Cream (Opzelura®) in Patients with Mild-to-Moderate Hidradenitis Suppurativa

March 10, 2024

From Incyte Corporation

Via Business Wire

Incyte Presents New Late-Breaking Data from Phase 2 Study Evaluating Povorcitinib in Patients with Prurigo Nodularis

March 10, 2024

From Incyte

Via Business Wire

3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise ↗

March 07, 2024

Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.

Via InvestorPlace

New Data from Incyte’s Growing Dermatology Portfolio to be Presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting

March 04, 2024

From Incyte

Via Business Wire

Incyte Launches The Unseen Journey to Elevate the Hidden Impact of Myeloproliferative Neoplasms (MPNs) on Patients’ Lives through Generative AI

February 29, 2024

From Incyte

Via Business Wire

Incyte Announces U.S. Food and Drug Administration Grants Priority Review for Axatilimab for the Treatment of Chronic Graft-Versus-Host Disease

February 27, 2024

From Incyte

Via Business Wire

< Previous 1 2

...

13 14 15 16 17 18 19 20 21

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.